Bridging therapy with airway stent placement followed by immune checkpoint inhibitors in patients with lung cancer and malignant airway disorders: A retrospective study.
1/5 보강
PICO 자동 추출 (휴리스틱, conf 3/4)
유사 논문P · Population 대상 환자/모집단
13 patients, and oxygen was discontinued in 10.
I · Intervention 중재 / 시술
anticancer therapy after airway stent placement from January 2016 to July 2025
C · Comparison 대조 / 비교
추출되지 않음
O · Outcome 결과 / 결론
[CONCLUSIONS] Airway stenting can improve PS, relieve obstruction, and permit safe ICI therapy. Subsequent ICI use may extend survival and increase stent removal rates, supporting stenting as a bridging approach in oncologic airway emergencies.
[BACKGROUND] Airway stent placement is used to manage malignant airway obstruction, but often these patients cannot receive immune checkpoint inhibitors (ICIs) because of poor performance status (PS).
- p-value p = 0.03
- p-value p = 0.007
- 95% CI 120-546
APA
Takigawa Y, Sato K, et al. (2026). Bridging therapy with airway stent placement followed by immune checkpoint inhibitors in patients with lung cancer and malignant airway disorders: A retrospective study.. Respiratory investigation, 64(3), 101403. https://doi.org/10.1016/j.resinv.2026.101403
MLA
Takigawa Y, et al.. "Bridging therapy with airway stent placement followed by immune checkpoint inhibitors in patients with lung cancer and malignant airway disorders: A retrospective study.." Respiratory investigation, vol. 64, no. 3, 2026, pp. 101403.
PMID
41833213 ↗
Abstract 한글 요약
[BACKGROUND] Airway stent placement is used to manage malignant airway obstruction, but often these patients cannot receive immune checkpoint inhibitors (ICIs) because of poor performance status (PS). We evaluated whether stenting could enable ICI therapy and improve outcomes.
[METHODS] We retrospectively reviewed patients with lung cancer who received anticancer therapy after airway stent placement from January 2016 to July 2025. Outcomes included 1-year overall survival (OS), median survival time (MST), ECOG PS changes, complications, immune-related adverse events, and stent removal.
[RESULTS] Eighteen patients were included (16 non-small cell lung cancer; 2 small cell lung cancer). Median age was 71 years, and 60% had poor PS. MST was 282 days (95% CI, 120-546). MST was longer in stage III than stage IV disease (502 vs 200 days; p = 0.03) and in patients with PS 1 versus 2 after stenting (398 vs 78.5 days; p = 0.007). ECOG PS improved in 13 patients, and oxygen was discontinued in 10. Immune-related adverse events occurred in 7 patients and stent-related complications in 9; stent removal was performed in 8 cases (41%). MST was longer with ICI-containing therapy than with chemotherapy and/or radiotherapy (282 vs 139 days; p = 0.002). Stent removal was more frequent in the ICI group (44.4% vs 13.0%; p = 0.03).
[CONCLUSIONS] Airway stenting can improve PS, relieve obstruction, and permit safe ICI therapy. Subsequent ICI use may extend survival and increase stent removal rates, supporting stenting as a bridging approach in oncologic airway emergencies.
[METHODS] We retrospectively reviewed patients with lung cancer who received anticancer therapy after airway stent placement from January 2016 to July 2025. Outcomes included 1-year overall survival (OS), median survival time (MST), ECOG PS changes, complications, immune-related adverse events, and stent removal.
[RESULTS] Eighteen patients were included (16 non-small cell lung cancer; 2 small cell lung cancer). Median age was 71 years, and 60% had poor PS. MST was 282 days (95% CI, 120-546). MST was longer in stage III than stage IV disease (502 vs 200 days; p = 0.03) and in patients with PS 1 versus 2 after stenting (398 vs 78.5 days; p = 0.007). ECOG PS improved in 13 patients, and oxygen was discontinued in 10. Immune-related adverse events occurred in 7 patients and stent-related complications in 9; stent removal was performed in 8 cases (41%). MST was longer with ICI-containing therapy than with chemotherapy and/or radiotherapy (282 vs 139 days; p = 0.002). Stent removal was more frequent in the ICI group (44.4% vs 13.0%; p = 0.03).
[CONCLUSIONS] Airway stenting can improve PS, relieve obstruction, and permit safe ICI therapy. Subsequent ICI use may extend survival and increase stent removal rates, supporting stenting as a bridging approach in oncologic airway emergencies.